Trial Profile
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Fenfluramine (Primary)
- Indications Dravet syndrome
- Focus Adverse reactions; Registrational
- Sponsors Zogenix
- 22 Sep 2023 primary endpoints has been amended
- 25 Feb 2023 Status changed from active, no longer recruiting to completed.
- 06 Dec 2022 Interim results (n=343, Cutt off date : November 1, 2021) presented at the 76th Annual Meeting of the American Epilepsy Society.